Investor AB (publ) (INVEA) Earnings Call Transcript & Summary
October 16, 2026
Earnings Call Speaker Segments
Jacob Lund
executiveGood morning, and welcome to Investor's results call for the third quarter of 2026. I'm joined here in the studio by our CFO, Jenny Haquinius; and our CEO, Christian Cederholm. And after their presentations, we will be opening up for questions, both on the call via our operator as well as online. And with that, over to you, Christian.
Christian Cederholm
executiveThank you, Jacob, and hi, everyone. In Q3, adjusted net asset value grew by 4% and total shareholder return for the Investor B share was 1%. All business areas contributed to growth with particularly strong performance in Patricia Industries. At the end of the third quarter, adjusted net asset value stood at SEK 1,258 billion. Let me briefly go through the 3 business areas: Listed Companies, Patricia Industries and investments in EQT, starting with Listed Companies. Listed Companies generated a total return of 1% in Q3 with Saab and SEB contributing strongly. As previously mentioned, ABB announced its USD 5.5 billion acquisition of Rotork, strengthening its position within industrial automation by adding a portfolio of electric actuators for controlling valves. This is a significant acquisition for ABB and a good example of how add-ons can be used to complement organic growth in strategic areas. Together with AT&T, in July, Ericsson demonstrated drone detection based on existing 5G infrastructure using advanced network sensing and AI. This highlights how Ericsson's leading radio technology can extend into applications also beyond connectivity. Sobi's, Guido Oelkers and SEB's, Johan Torgeby have announced their departures. And we would like to take this opportunity to thank them both for their significant contributions. We're pleased that Jonas Ahlström has stepped in as interim CEO at SEB. And in Sobi, the Board leads the search for a new CEO. The Nomination Committee is currently preparing for the 2027 AGM season. Competition for top competence is intense and global and we will, hence, continue to push to close the gap between Swedish and international board remuneration levels for Listed Companies. Now over to Patricia Industries, where total return was 15% driven by strong operating performance, further supported by multiple expansion and positive currency impact. For the major subsidiaries, organic sales growth was 7% and adjusted EBITDA grew by 26%. This was boosted by M&A, some FX tailwind as well as a few percentage points from tariff refunds. But first and foremost, the underlying performance was strong, with solid underlying leverage in most places. A few highlights then. Mölnlycke announced its intended separation, creating 2 even more focused companies all with the intention to create even better basis for each business to reach closer to their full potential. I will come back to this shortly. Nova Biomedical performed strongly with healthy growth in both bio and clinical and with efficiency improvement as the integration work continues. Vectura announced a major development project for a new R&D facility with Saab in Jönköping and Patricia Industries invested SEK 500 million to help finance this. Right after the end of the quarter, Vectura divested 2 elderly care facilities, all in line with its strategy of focusing on developing, owning and managing innovation clusters. Sarnova acquired Mercury Medical, a manufacturer of respiratory and anesthesia products adding a proprietary product portfolio to Sarnova's acute care and emergency preparedness businesses. This is another step, adding on products to the Sarnova portfolio as a complement to the distribution business. And finally, in July, Permobil distributed SEK 550 million to Patricia Industries. So on Mölnlycke, they announced its intention to separate into 2 stand-alone companies, Mölnlycke, where the Wound Care and the antiseptics business will reside, and Mölnlycke Surgical, where the ORS and the gloves business will reside. This creates stronger conditions for both companies and all 4 business units to reach their full potential and drive long-term value creation through sharper strategic focus, clearer accountability and even greater speed of execution. Currently, focus is, of course, on executing the split successfully while keeping momentum in the underlying business. We will revert to this as it develops. For the major subsidiaries and our 40% in Tre Skandinavien, revenues amounted to almost SEK 73 billion in the last 12 months and EBITDA was SEK 19 billion. And finally then, investments in EQT, our third business area. Total return was 7%, driven by both EQT AB and our fund investments. In the quarter, we invested SEK 0.7 billion in the funds net of exit proceeds. Activity remained high, EQT closed the acquisition of Coller Capital, complementing its portfolio with a strong platform in the secondaries market. Also after the quarter, EQT announced the acquisition of Stockbridge scaling its real estate platform, adding a sector specialist team with a local presence in the U.S. And as reflected in our recent acquisitions of shares in EQT AB, we remain confident in their continued ability to generate attractive returns for its investors and its shareholders. As I've said many times, we're confident in our platform. In particular, I'd like to highlight our portfolio of high-quality companies. In today's complex operating environment, they're doing a good job focusing on improving efficiency and strengthening resilience while investing for the future. Our companies have a strong starting point with excellent customer offerings and leading market positions. As engaged owners, we remain focused on building and supporting these companies, and we're confident that this will create shareholder value over time. With that, I leave the floor to you, Jenny.
Jenny Haquinius
executiveThank you, Christian, and good morning. So let's move over to the financials for the quarter. So in Q3 2026, adjusted net asset value was SEK 1,258 billion, and this implies an increase of 4% compared to Q2. For the quarter, the value uptick was driven by all business areas, but particularly strong performance in Patricia Industries, which was up 15%, followed by investments in EQT, which was up 7%. Now double-clicking on each of the business areas, starting with Listed Companies. Within Listed Companies, share price performance was mixed, particularly strong in terms of total return for Saab, SEB and NASDAQ with exposure to defense and financial markets, but a tougher quarter in terms of total return for industrials and consumer. Total return for Listed Companies portfolio was 1%, which is 1 percentage point behind SIXRX. As for absolute contribution, we see a similar pattern, although ABB is the biggest drag, given weight and size in our portfolio. And then moving on to Patricia Industries. Solid performance across the Patricia Industries companies in Q3. The major subsidiaries grew 7% organically and adjusted EBITA increased by 26%. The primarily due to strong operating performance, but also in part helped by M&A, positive FX and tariff refunds. And then double-clicking on performance across the companies in Patricia Industries, and I will comment on a few of them. Solid organic growth across all companies in North America at attractive margins. For Laborie, organic growth of 13% was driven by all business areas. And also this quarter, to a large extent by the Optilume urethral stricture product. Profitability for Laborie increased despite continued investments in commercial. Nova Biomedical grew 14% organically and profitability increased on the back of efficiency improvements from the ongoing integration. Integration work continues but performance thus far underpins the potential of this platform. Looking at the Nordics, Piab grew 5% organically, and this was driven by lifting automation and vacuum automation. Profitability increased in part due to tariff refunds and FX, but also on the back of operating leverage. Permobil saw yet another quarter with muted growth. But despite this and commercial investments, it's good to see solid profitability and focus for the company is on ongoing product launches to fuel growth. Moving on to Mölnlycke. Mölnlycke had a quarter with 5% organic growth, with growth driven by all 4 business areas. Focusing on Wound Care specifically, we saw 6% organic growth, driven by all regions, particularly strong quarter in Canada and good momentum in China and pockets of Europe. Wound Care U.S. showed organic growth, largely in line with the market, but we are seeing continued tough competition, and that's specifically within prevention. Profitability was largely in line with last year, also when adjusting for tariff reclaims and FX, and this is despite higher raw material and logistics costs. We saw a 15% increase in estimated market values for Patricia Industries comparing to Q2. So from SEK 222 billion to SEK 256 billion, and this increase was explained by expanding multiples earnings growth, solid cash flow generation and positive FX. And as a reminder, our multiple-based valuation method uses a 3-month value weighted price and not the quarter-end spot price. And the positive impact from FX comes from a weaker Swedish krona in Q3 compared to Q2. If we look at value development across companies, all companies contributed positively, and the main positive contribution came from Mölnlycke and Nova Biomedical. Also worth highlighting is the distribution of SEK 550 million from Permobil to Patricia Industries and the equity contribution to Vectura of SEK 500 million to fund the development of Saab's new R&D site in Jönköping. And then moving on to investments in EQT. Total value change was positive, so 7% in the quarter, and that's driven by both EQT AB and fund investments. And as a reminder, we report the EQT fund investments with 1 quarter lag. So the 9% is based on EQT's Q2 report. And then on the right-hand side, you see the net cash flow from EQT to Investor, which was negative in Q3, and that's because drawdowns were larger than proceeds. And here, we illustrate net cash flow from investments in EQT to Investors over time. It's quite lumpy on a quarterly basis. But over the past 10 years, we've received a net cash inflow of SEK 1.5 billion on average per year. And our balance sheet remains strong. Our leverage as of Q3 is 1.8%, and that remains in the lower end of our policy range, and we closed the quarter with SEK 29 billion in cash at hand. Also worth mentioning is that we, as part of the annual rating assessment were upgraded by Moody's from Aa3 to Aa2, and that reflects our strong track record, attractive portfolio of companies clear strategy and financial strength. And then on to my final slide, looking at the longer-term perspective, the performance of the Investor AB B share truly demonstrates the strength and the resilience of our portfolio and our strategy. And with that, I will leave the word back to Jacob.
Jacob Lund
executiveThank you, Jenny. Thank you, Christian. We are now ready to take your questions, and we will start with the questions through our operator, Sandra, please.
Operator
operator[Operator Instructions] We will now take our first question from the line of Derek Laliberte from ABG Sundal Collier.
Derek Laliberte
analystAnd my first question relating to Mölnlycke. We did see the Wound Care growth here accelerating to 6% in the quarter from a relatively weaker first half. So I know you mentioned all regions contributing, et cetera, but what would you say has driven this improvement? Is it mainly better market conditions? Or are you seeing sort of stronger underlying execution and market share gains? And how do you view sort of the sustainability of this growth going forward?
Jenny Haquinius
executiveI can start. Thank you for the question. Yes, we are looking at a solid quarter for Mölnlycke and Wound Care specifically in terms of organic growth. But I would be careful to draw any too clear conclusions based on one single quarter. We alluded to before that if we look at the underlying kind of market growth for the more mature wound care market, which is the larger share of the Wound Care sales from Mölnlycke that is low to mid-single digits. So in the context of that, it's a good quarter. But I do want to highlight that we continue to see some tough and challenging markets. We have France, which continue to have a lot of pressure on health care budgets. And in the U.S. specifically, we also see tough competition, and that's within prevention. But nevertheless, Mölnlycke, it did grow in the U.S. in line with the market. And I think that comes down to really strong execution. Mölnlycke has a premium product offering and has done really, really well in terms of execution of go-to-market. But also, as mentioned, it is a broad-based growth. So it is driven by all regions essentially we see particularly strong growth in Canada for this quarter, continued momentum in China.
Derek Laliberte
analystOkay. Great. I appreciate the flavor there. And also on Mölnlycke, you obviously announced the planned separation of surgical. And we also know and you disclosed the sort of significant profitability difference between the 2 parts here. So beyond this greater focus and et cetera, where do you see the largest opportunities going forward for value creation in the [indiscernible]? And should we expect the separation to improve profitability in either of the businesses? Or is it more about accelerating growth?
Christian Cederholm
executiveThank you. I'll start then. The intention to separate this basically should be seen as another step of creating even more focus and accountability in each of the businesses so as to ensure that we have the best possible basis for each business to reach their full potential. As you say, the businesses are different in terms of financial profile, et cetera. And that's, I guess, one of the reasons why we think separating them makes sense. And then in terms of the potential, I mean, there's different things to work on in all of the business. I think one common theme worth highlighting is that we want to increase the level of innovation over time in Mölnlycke really across the businesses.
Derek Laliberte
analystPerfect. And on Nova, obviously, here continues to deliver really impressive growth and profitability. How much would you say this current margin improvement is driven by the integration synergies versus, I guess, underlying operating leverage and how much further potential do you see from the integration?
Jenny Haquinius
executiveWell, that's a good question. And I think we are in quite early days still in terms of integration, there's a lot more work to be done. And as we've alluded to before, there might be some added volatility, but we are seeing efficiency coming from the integration. But at the same time, the company is also investing in G&A, and we'll also continue to invest in G&A, in innovation and also commercial going forward to really make sure that we build a strong platform. So I think we'll have to kind of wait and see throughout the integration. At the same time, the quarter really kind of underpins the strength of this platform going forward.
Derek Laliberte
analystThank you. And finally, on Laborie, I think we touched upon this previously, but delivering another strong quarter with 13% organic growth. How much would you say that this strong momentum is coming from the established businesses versus the newer Optilume products, for example, and how do you see the growth outlook going forward for these products?
Jenny Haquinius
executiveWell, in the quarter, we're seeing a growth contribution from all business areas, which is great. But also for this quarter, the main contribution is urology and that's specifically the Optilume urethral stricture. And I think when we have these product launches and the new products growth will likely not be linear. But I think we are really optimistic about the momentum going forward, both for Optilume urethral stricture, but I think it's also good to see in this quarter where we see good growth in the child and maternal health on the back of the Jada acquisition. So the company will continue to be focused on innovation to further fuel growth.
Derek Laliberte
analystOkay. On the -- could you remind us what the status is of the BPH launch for Optilume.
Jenny Haquinius
executiveYes, of course. Well, the BPH product is in a much earlier stage of the launch cycle. I think if you remember, the company received the first reimbursement code in the U.S. earlier this year, and the work right now for Laborie is to make sure that you build clinical evidence and you do that in close collaboration with physicians. And that, of course, takes a bit of time because you need to ensure high quality and reliability of that data. But that's in line with kind of the plan for the launch, but it's much earlier if you compare it to Optilume urethral stricture.
Operator
operatorWe will now take the next question from the line of Linus Sigurdson from DNB Carnegie.
Linus Sigurdson
analystSo starting with the question on Mölnlycke. I wanted to double click on China. You mentioned strength in that market. Is there anything you would highlight in China? And how far along is this Zhende JV that you announced earlier this year?
Jenny Haquinius
executiveI can start. I think Mölnlycke has had a focus on China for quite some time, but quite recently built an own manufacturing site. And as you mentioned from last quarter, also announced a JV with Zhende, but that's very early days. So the growth in China that we're seeing right now, it's not on the back of the joint venture. So there are more opportunities within that lies ahead. but we do see continued organic growth, we're also coming from a relatively low base.
Christian Cederholm
executiveAnd it could be worth just to add there on China, unlike most of the rest of Mölnlycke in China, we basically have 2 businesses. One is the traditional hospital health care business, and there is also a rather healthy business-to-consumer line in China as well.
Linus Sigurdson
analystOkay. Appreciate it. And then a second one on Mölnlycke. On ORS, I mean, growth there has clearly lagged the overall group for quite some time now heading into this proposed split. Can you just remind us how much of that, say, underperformance is driven by a slower market compared to, say, Wound Care, for example?
Jenny Haquinius
executiveI can start. Well, within ORS, we have typically, the growth is driven by the number of procedures, so like operating procedures, and there is structural underlying growth. At the same time, what Mölnlycke really offers for the customers with the ORS of the surgical trays is to address the efficiency in the OR. So I think based on the health care pressure that we're seeing globally, there's a very clear case for Mölnlycke to actually grow beyond that if we're looking ahead. But there is tough competition I think the moat for kind of Mölnlycke offering is that it's a high level of customization for the surgeon, which also means that you unlock even further efficiencies in the OR.
Christian Cederholm
executiveI think worth remembering for ORS, it's primarily a European business.
Linus Sigurdson
analystRight. Okay. But would it be fair to say that the sort of penetration level that they've been able to reach has been perhaps below where you had expected?
Christian Cederholm
executiveI would not say that. I think there is, to Jenny's point, I think there is more penetration to be had. And then where would we like to be now? Well, always further ahead, of course, but there is a strong case for continued penetration.
Linus Sigurdson
analystOkay. And then finally, on Laborie, could you quantify what the positive margin impact was from this tariff refund?
Jenny Haquinius
executiveWell, I would say for Laborie, it was roughly -- I would say generally for all the companies, it's roughly 1 percentage point on the margin that comes from tariff refunds.
Christian Cederholm
executiveOr those where we highlighted tariff refunds.
Operator
operatorWe will now take the next question from the line of Björn Olsson from SEB.
Bjorn Olsson
analystJust to follow up what you said earlier, Christian, you said that one of the motivations for the split of Mölnlycke was to increase focus and accountability. Could you give any flavor of which parts of Mölnlycke do you see have been lacking this in the past?
Christian Cederholm
executiveWell I wouldn't say it's been lacking, but I would say that our experience from separating businesses is that -- I mean, it's hard to capture in PowerPoint or Excel but the level of focus and accountability that you achieve by providing even more separate P&Ls and separate boards, et cetera, is not insignificant.
Bjorn Olsson
analystOkay. Fair enough. So if we then look at that situation. I mean having two boards, two overhead functions to back office staff, I mean, that drives costs as well on a very often quite significant manner. Do you see that cost headwind to be mitigated by different baskets of peer multiples near term in the two separate companies or do you see this as a potential strategic optionality as well to divest surgical maybe?
Christian Cederholm
executiveI'll maybe if I start, I mean, on your first question around extra cost, you're spot on. I mean, separation typically means that you will have to you will have to duplicate certain costs and functions and whatnot. And again, that's fairly easy to capture ahead of it. And the value and the potential is harder to quantify. But over and over again, we have seen how greater accountability and focus drives value. Then on your second question in terms of multiples, I'm not sure I fully understood it, but let me try to answer and then you guide me if I was on it or not. The motivation for separating is not to sell one or both of the companies, nor is it to sort of enhance valuation by way of applying a different peer set. We'll obviously come back to and see what the peer group looks like, but that's not the motivation here.
Bjorn Olsson
analystOkay. Fair enough. So then on a performance basis, when would you expect that this will turn into a positive? I mean, after you'll naturally have a short period of higher costs and reorganizations always consume energy from organizations. But when do you expect this to be a net positive to -- from a sum of the parts perspective, is it end of '27 or '28 or when -- what's the sort of indicative time line?
Christian Cederholm
executiveI wish I could give you a clear answer. But I think you're on it in terms of the dynamics here. So focus right now is, of course, to execute on the split while -- and this is important, keeping momentum in the underlying businesses and then we'll see what happens.
Bjorn Olsson
analystI guess, like you say, easier said than done but good luck with it anyway.
Christian Cederholm
executiveThank you.
Operator
operatorWe will now take the next question from the line of Oskar Lindstrom from Danske Bank.
Oskar Lindström
analystYes. You sold -- was it 2 million SEB shares and agreed to sell, I think, about 2 million more. Is it sort of a standing policy that you will sell SEB shares to sort of offset SEB's buybacks? And would you plan to do a sort of a similar policy, if that is a policy for your other listed holdings?
Christian Cederholm
executiveThank you for the question. No, it's not a policy. It's driven by regulatory considerations, specifically around SEB. And even in SEB, it's not a policy, but I mean, clearly, you've seen a pattern. And what we've said before is that we're comfortable staying at roughly the ownership levels that we are.
Operator
operatorWe will now take the next question from the line of Johan Sjöberg from Nordea.
Johan Sjoberg
analystCould you talk a little bit more about the tariff impact? You mentioned 1 percentage point in -- on margins. We had -- if you look at -- can you please sort of just give an up -- what did you say about the tariff impact in Q2 on for that? And also, do you expect further tariff impact in Q4 and possibly into Q1 as well? Or how -- could you give some sort of guidance on that, please?
Christian Cederholm
executiveLet me start with the forward-looking part. To the best of our knowledge, we've seen the majority of tariff refunds. But again, this is an area that is moving quite rapidly as we all know. So let's see. But to our best of knowledge, we've seen the most of it.
Johan Sjoberg
analystAnd if you compare the tariff impact in Q3 versus Q2, was that sort of similar? Or I'm just trying to elaborate a little bit about how to estimate next year's margins?
Christian Cederholm
executiveIt was slightly less in Q2. I -- as per my recollection.
Johan Sjoberg
analystSo peaking Q3? Okay. Good. All right. And then also, I know you're not super keen on talking about sort of the -- your Mölnlycke and Laborie and also Nova Biomedical's future growth here. But maybe you can give some sort of guidance on the underlying markets. So -- because this is a bit tricky for us to have a clear view. So if you could provide some insight how do you view their underlying markets, not the individual companies, but more of their actual markets growing, that would be fantastic.
Jenny Haquinius
executiveYes. Well, I think Mölnlycke we typically talk about quite a lot where we have the kind of underlying market growth in the more mature markets of the low to mid-single digits. If we talk specifically about Wound Care. But then, of course, we're seeing higher market growth in more kind of growth markets. And if we take Nova as an example, had both the clinical and the biopharma, I think we look at the company in this quarter, we do have a somewhat easier comp. So because we have the cyber incident from last year. So here, we might be more relevant to look at kind of what the historical average has been for the two companies, which has been around 8%, and they've also been able to take some share if that provides some guidance. And then on Laborie, it's more difficult because here, you have a lot of new products that are entering the market. So I think here, it will be more volatile. I think it's hard to provide. And I think also referring to at the Capital Markets Day, which is upcoming. I think it's also a really great opportunity to have that dialogue with the CEOs. And we have all of the North American companies presenting and also Mölnlycke.
Johan Sjoberg
analystI think that is a fantastic thing actually because I think this is something which I think is something which is on everyone's mind here and sort of what is the underlying market drive sort of what some sort of figure that is fantastic if they could provide that, especially for the larger ones. And it's very -- also very nice to see that the size of the other companies in Patricia is not just -- they are growing. So of course, Mölnlycke is, by far, the biggest one, but it's catching up with that. So that's very good. Last and final thing, just on the tariff. Obviously, you have raised your own prices to offset the tariffs. Was there some sort of surcharge here? Or is that could sort of come back if now when tariffs are disappearing? Or is that just pure actually list price increases?
Christian Cederholm
executiveIt's a great question. And it's really -- it's a mix, but we don't foresee any major sort of reversals as of now.
Operator
operator[Operator Instructions] Our next question comes from the line of Hannah Leivdal from Citi.
Hannah Leivdal
analystJust one question from me on the back of the increased stake in EQT today. So just kind of a bigger picture question, looking forward, where do you see the largest incremental contributors to your NAV growth over the next 3 to 5 years? What areas are you most excited about? Is it the listed holdings, the Patricia Industries or the continued growth in the EQT platform. Obviously, you have a very strong balance sheet position, right now. So there's a lot of a lot of room and runway. So how do you think about that? And where would you prioritize?
Christian Cederholm
executiveI mean, thanks for the question. We love all our children equally. So in terms of capital allocation priorities, what we've said clearly is that number one is to continue to build and support the existing companies. Number two is to pay a steadily rising dividend, and then number three, but still important is to find new platform companies over time. Now if you look at this in a slightly longer perspective, you will see that there's been quite significant investment in all 3 business areas. Now of course, quarter-to-quarter and even maybe year-to-year, it will vary. And we have deliberately not set a target where we sort of allocate X to one business area or the other, but rather we want to have all the good opportunities surface and then we pick from there.
Operator
operatorThere are no further questions on the phone at this time. I would like to hand back over for webcast questions now.
Jacob Lund
executiveThank you, Sandra. And let's take the question from the web. We start with one from [ Michael Gilkens ]. ABB is an important position, which benefits from the optimism around the build-out of AI, would Investor AB be willing to actively manage the position and trim when it becomes too large or expensive similar to how investor buys during market drawdowns?
Christian Cederholm
executiveOkay. Thank you for the question. The short answer is no. Selling sort on the margin is not really a tool in our toolbox as we see it. We think that this is not really helpful for our strategy of being a long-term and engaged owner. Now on ABB, they've clearly done well. I would say it represents maybe 20% or so of our net asset value today. I would emphasize though that ABB is, of course, not one business but underlying ABB is a number of different businesses.
Jacob Lund
executiveThank you. Then we had a question from [ Ken Slaski ] at Deutsche Bank that I think has been covered because around the Wound Care market conditions. Next one, [ Alexandre ] there is the Mölnlycke split a second response to increasing Chinese competition.
Jenny Haquinius
executiveYes, I can start. Yes. I think Christian explained it very well, kind of the purpose of the separation. To increase focus and to create even better prerequisites for full potential of both the businesses going forward. And in part, we see an opportunity to accelerate innovation even further. And that is, of course, to make sure that both businesses remain competitive over time. So I wouldn't say that it's linked to Chinese competition specifically, but I think overall, a competitive global market.
Jacob Lund
executiveThank you. And we have another one from [ Michael Gilkens ]. Europe seems to be falling behind on economic -- important economic growth themes like AI build-out relative to China and the U.S. The Draghi report is still not finding momentum within the continent. Does this impact your ambitions with regard to portfolio composition, particularly within Patricia Industries.
Christian Cederholm
executiveI can start. Thank you for the question. And I would largely agree with your description of where we are. I would also highlight, though, that Europe remains a very important market for many of our companies. And if I see the glass as half full, the Draghi report, as you say, and the Letta Report points out a clear direction. In our view, we feel that there is great momentum and alignment around what needs to be done then, of course, doing it is it will require a lot of work and compromises and whatnot. But as if for as we get there, there is also a lot of potential in Europe. And if I have to pick one sort of factor, it is if we can create more potential and realize the full potential of a single market, be it around services, goods, capital, labor, et cetera. That's a great potential. And we need to be wary that it's a highly competitive world. And at the moment, to your point, Europe is not in the lead.
Jacob Lund
executiveAnd we have a couple of questions from [ Holger ] [indiscernible]. I think the first one regarding the Mölnlycke split has been covered already. So I'll jump to the second one. There is now a wide dispersion in operating performance within Patricia with Nova and Laborie performing very strongly, while other businesses are more challenged. How do you think about allocating incremental capital between the strongest compounders and the businesses that require more operational improvement?
Christian Cederholm
executiveThank you. I can start. I think generally, our way of approaching growth in general and in particular, maybe M&A is we always look for stability, profitability and then growth. And to the extent we have businesses or parts of businesses that are not performing the way we want, then the focus is typically on making sure we get to the right level before we sort of pushed the accelerator further.
Jenny Haquinius
executiveThen maybe just adding to that. If we look at the quarter, I agree, Nova has a good quarter, Laborie the same. But if I would say BraunAbility is also performing well this quarter and also Sarnova. So looking at the full North American portfolio. And in terms of the Nordic portfolio, we have a good quarter from Mölnlycke and also, Piab. And so if we single out Permobil and maybe for this quarter, there are a few reasons for why growth is muted. We do still decent profitability. But for Permobil, there are a lot of focus on ongoing product launches to also fuel growth. I think for the context for this, I think we are seeing a broader kind of performance than maybe what the question is alluding to here, but I agree with your point.
Jacob Lund
executiveAnd the final question doesn't have a name attached to it, but I'll make an exception since it's a short one. Will you consider making more buyback returning to shareholders?
Jenny Haquinius
executiveI can start. Yes, I think Christian has partly already answered that. Our capital allocation priorities are very clear and the are very firm. First and foremost, we are to invest and support and grow our companies that we have in our portfolio today and then paying a steadily rising dividend and also looking to add new platforms to the portfolio. So that's our kind of main focus. And we do have a strong balance sheet, and I think we're very glad that we do. It's a quite volatile environment, and we want to always have the opportunity to act when we find really attractive investment opportunities.
Jacob Lund
executiveGood. Then I can't see any further questions, and that means it's time to conclude. So many thanks, Jenny, many thanks, Christian, and all of you who have participated. Our next report is the full year and Q4 report on January 22 next year. However, as we mentioned, do not miss our Capital Markets update on November 4, where we will deep dive into a number of the companies in the Patricia Industries portfolio. All the North American companies are here with their CEO as well as Mölnlycke. So hope to see you here. And until then, thank you, and goodbye.
Jenny Haquinius
executiveThank you.
Christian Cederholm
executiveThank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Investor AB (publ) transcript — plus 261,000+ transcripts from 13,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Investor AB (publ) earnings transcripts and 261,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Investor AB (publ) or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.